Our research group is developing novel transporter-utilizing (pro)drugs to:
- Improve the drug delivery across the blood-brain barrier (BBB) and selectively into different cell types (neurons, astrocytes or microglia) within brain (intra-brain targeting)
- Explore if dual targeting of LAT1-utilizing compounds into the brain and simultaneously into the pancreas (brain-pancreas axis) can have beneficial effects on the treatment of neurodegenerative diseases
- Target chemotherapeutics (prodrugs or drug analogues) selectively into the cancer cells
- Inhibit specific transporter's (influx or efflux) function to block nutrient delivery into the cancer cell or drug efflux out of the cancer cells (chemoresistance) to increase antiproliferative effects
- Modulate the expression of specific transporter's (influx or efflux) to regulate nutrient uptake (e.g. amino acids) or toxin uptake e.g., into the brain that can affect the progession of neurological diseases, or into specific cells, like cancer cells
In our research group we focus on the journey of lifelong learning, although the scientific road can be a daily roll-a-coaster.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.